Thomas J. Tisch is Director at SYNAGEVA BIOPHARMA CORP (GEVA). They have made 5 open-market trades across 2 companies since 2012, most recently 2017-01-10.
CIK 0001081916
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $51.7M since 2012, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SHLD | BUY | 2014-04-15 | 2014-04-17 | $33.56 | $15.9M | -8.7% | -3.4% | -3.4% |
| GEVA | BUY | 2013-01-09 | 2013-01-15 | $47.53 | $1000K | N/A | N/A | N/A |
| GEVA | BUY | 2012-07-12 | 2012-07-13 | $41.20 | $1.5M | N/A | N/A | N/A |
| GEVA | BUY | 2012-01-10 | 2012-01-11 | $25.18 | $30.2M | N/A | N/A | N/A |
| GEVA | BUY | 2012-01-10 | 2012-01-17 | $25.18 | $3.0M | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.